Results 31 to 40 of about 2,525 (153)

Rapid Detection of KPC-Producing Enterobacterales Susceptible to Imipenem/Relebactam by Using the MALDI-TOF MS MBT STAR-Carba IVD Assay

Frontiers in Microbiology, 2020
KPC-producing Enterobacterales represent a serious public health concern. Limited therapeutic options are available for treatment, however, the novel combination of imipenem/relebactam represents a promising alternative.
Marina Oviaño, Eva Gato, Germán Bou
doaj   +1 more source

Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options

Frontiers in Microbiology, 2019
Carbapenems are considered as last-resort antibiotics for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in clinical practice, the emergence of carbapenem-resistant pathogens now ...
Chau-Chyun Sheu, Chau-Chyun Sheu, Ya-Ting Chang, Ya-Ting Chang, Shang-Yi Lin, Shang-Yi Lin, Yen-Hsu Chen, Yen-Hsu Chen, Yen-Hsu Chen, Po-Ren Hsueh, Po-Ren Hsueh   +10 more
doaj   +1 more source

Role of Relebactam in the Antibiotic Resistance Acquisition in Pseudomonas aeruginosa: In Vitro Study

Antibiotics, 2023
Background: Pseudomonas aeruginosa shows resistance to several antibiotics and often develops such resistance during patient treatment. Objective: Develop an in vitro model, using clinical isolates of P. aeruginosa, to compare the ability of the imipenem
Maria Paz Ventero, Jose M. Haro-Moreno, Carmen Molina-Pardines, Antonia Sánchez-Bautista, Celia García-Rivera, Vicente Boix, Esperanza Merino, Mario López-Pérez, Juan Carlos Rodríguez   +8 more
doaj   +1 more source

Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT Pseudomonas aeruginosa is a prevalent and life-threatening Gram-negative pathogen. Pseudomonas -derived cephlosporinase (PDC) is the major inducible cephalosporinase in P. aeruginosa .
Melissa D, Barnes, Christopher R, Bethel, Jim, Alsop, Scott A, Becka, Joseph D, Rutter, Krisztina M, Papp-Wallace, Robert A, Bonomo   +6 more
openaire   +2 more sources

Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors

Pharmacy, 2019
Although beta-lactam allergies are an emerging focus of stewardship programs and interventions, less is publicly released regarding allergies to beta-lactamase inhibitors. This review presents and evaluates the data regarding allergic reactions with beta-
Kayla R. Stover, Katie E. Barber, Jamie L. Wagner   +2 more
doaj   +1 more source

Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition

Molecules, 2022
Antibacterial resistance towards the β-lactam (BL) drugs is now ubiquitous, and there is a major global health concern associated with the emergence of new β-lactamases (BLAs) as the primary cause of resistance.
Zafar Iqbal, Jian Sun, Haikang Yang, Jingwen Ji, Lili He, Lijuan Zhai, Jinbo Ji, Pengjuan Zhou, Dong Tang, Yangxiu Mu, Lin Wang, Zhixiang Yang   +11 more
doaj   +1 more source

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase

Antibiotics, 2023
Background: Ceftazidime-avibactam was approved by the FDA to treat infections caused by Enterobacterales carrying blaKPC-2. However, variants of KPC-2 with amino acid substitutions at position 179 have emerged and confer resistance to ceftazidime ...
Krisztina M. Papp-Wallace, Melissa D. Barnes, Magdalena A. Taracila, Christopher R. Bethel, Joseph D. Rutter, Elise T. Zeiser, Katherine Young, Robert A. Bonomo   +7 more
doaj   +1 more source

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections [PDF]

Open Forum Infectious Diseases, 2021
Abstract A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred
Nicholas Rebold, Taylor Morrisette, Abdalhamid M Lagnf, Sara Alosaimy, Dana Holger, Katie Barber, Julie Ann Justo, Kayla Antosz, Travis J Carlson, Jeremy J Frens, Mark Biagi, Wesley D Kufel, William J Moore, Nicholas Mercuro, Brian R Raux, Michael J Rybak   +15 more
openaire   +2 more sources

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

BMC Microbiology, 2019
Background The prevalence of antibiotic resistance is increasing, and multidrug-resistant Pseudomonas aeruginosa has been identified as a serious threat to human health. The production of β-lactamase is a key mechanism contributing to imipenem resistance
Katherine Young, Ronald E. Painter, Susan L. Raghoobar, Nichelle N. Hairston, Fred Racine, Douglas Wisniewski, Carl J. Balibar, Artjohn Villafania, Rumin Zhang, Daniel F. Sahm, Timothy Blizzard, Nicholas Murgolo, Milton L. Hammond, Mary R. Motyl   +13 more
doaj   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source